NeuroNova Overview

  • Founded
  • 1998
Founded
  • Status
  • Acquired/​Merged
  • Latest Deal Type
  • M&A
  • Latest Deal Amount
  • $19.1M
Latest Deal Amount

NeuroNova General Information

Description

Developer and provider of novel therapies for the treatment of disorders of the central nervous system. The company also develops novel therapeutic products based on neurogenesis in areas of high unmet medical need in neurodegenerative diseases.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Primary Industry
Therapeutic Devices
Primary Office
  • Fiskartorpsvägen 15 A-D
  • SE-114 33 Stockholm
  • Sweden
+46 08-786 00 00
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

NeuroNova Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Merger/Acquisition 17-Dec-2012 $19.1M 000.00 000.00 Completed Generating Revenue
5. Grant 01-Jan-2008 00000 000.00 Completed Product Development
4. Later Stage VC 01-Feb-2007 000.00 000.00 Completed Product Development
3. Early Stage VC 10-Sep-2003 000.00 000.00 Completed Product Development
2. Early Stage VC 20-Mar-2000 $3.45M $3.45M Completed Product Development
1. Seed Round Completed Startup
To view NeuroNova’s complete valuation and funding history, request access »

NeuroNova Patents

NeuroNova Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-1750752-A2 Compounds and methods for increasing neurogenesis Withdrawn 20-Nov-2003 000000000
CA-2546843-C Compounds and methods for increasing neurogenesis Expired - Fee Related 20-Nov-2003 000000000
CA-2546843-A1 Compounds and methods for increasing neurogenesis Granted 20-Nov-2003 000000000
US-6969702-B2 In patient exhibiting disorder selected from neurodegenerative disorders, ischemic disorders, neurological traumas, and learning and memory disorders; calcitonin, exendin and their analogs that elevate intracellular camp levels in the tissue Active 20-Nov-2002 000000000 00
US-20050009742-A1 In patient exhibiting disorder selected from neurodegenerative disorders, ischemic disorders, neurological traumas, and learning and memory disorders; calcitonin, exendin and their analogs that elevate intracellular camp levels in the tissue Granted 20-Nov-2002 A61K35/30 00

NeuroNova Executive Team (4)

Name Title Board Seat Contact Info
Anders Haegerstrand Chief Executive Officer
Henrik Resmark Chief Financial Officer
You’re viewing 2 of 4 executive team members. Get the full list »

NeuroNova Former Investors (4)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
HealthCap Venture Capital Minority 000 0000 000000 0
Novare Kapital Venture Capital Minority 000 0000 000000 0
Patricia Industries PE/Buyout Minority 000 0000 000000 0
Scandinavian Life Science Venture Venture Capital Minority 000 0000 000000 0
To view NeuroNova’s complete investors history, request access »